Amanat Acquisition Signs $377M M&A Deal with Corxel Pharmaceuticals, Inc.
Amanat Acquisition Corp (AMAN) has entered into a definitive business combination agreement with Corxel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on oral obesity therapies. The transaction is expected to provide approximately $377 million in gross proceeds, including a $300 million PIPE investment from institutional investors. Upon closing, expected in the first half of 2027, the combined company will focus on advancing Corxel's oral GLP-1 receptor agonist, CX11, into Phase 3 clinical trials.
- Value
- $377M
- Counterparty
- Corxel Pharmaceuticals, Inc.